Emory Technology Transfer’s Post

🔬✨ In this week's #TechTales post, we delve into our #nanoshuttle technology🚀 MOF nanoparticles are created by repeating a unit cell, forming a network with symmetrically repeated porosity. This intricate structure allows for exceptional adsorption properties, which is key to improved cargo uptake. At Vector Bioscience Cambridge, we leverage the porosity of MOFs to encapsulate small- and macro-molecules, enabling more effective and targeted drug delivery. This innovative approach supports the development of novel cancer treatments, enhancing patient outcomes. Stay tuned for our next #TechTales posts as we continue to explore the science driving our breakthroughs🧬💊🔬 #DrugDelivery #Nanotechnology #Biopharma #Innovation #MOFs #Science #Biotech #CancerTreatment #ResearchAndDevelopment

From Breaking Bad to Biotechnology: Exploring the New Frontier Join us as we dive into the fascinating world of biotechnology, from the iconic TV series Breaking Bad to the latest advancements in cell therapy. Discover how purified antibodies are revolutionizing medicine and how this cutting-edge field combines both passion and practicality. #BreakingBad #Biotechnology #CellTherapy #MedicalAdvancements #PurifiedAntibodies #ScienceAndTechnology #BiotechRevolution #MedicalInnovation #CellularResearch #HealthcareAdvances

From Breaking Bad to Biotechnology: Exploring the New Frontier Join us as we dive into the fascinating world of biotechnology, from the iconic TV series Breaking Bad to the latest advancements in cell therapy. Discover how purified antibodies are revolutionizing medicine and how this cutting-edge field combines both passion and practicality. #BreakingBad #Biotechnology #CellTherapy #MedicalAdvancements #PurifiedAntibodies #ScienceAndTechnology #BiotechRevolution #MedicalInnovation #CellularResearch #HealthcareAdvances

Fully automated workflow enabling high-throughput clinical proteomics 👉 Free access at https://lnkd.in/d6MfWcnj (Molecular and Cellular Proteomics, June 2024)   📑 Complex clinical problems sometimes require complex solutions - or at least robots and cutting-edge technology.   📠 In this study led by Anders H. Kverneland, we use liquid chromatography tandem mass spectrometry-based (LC-MS/MS) proteomics with an automated sample preparation to investigate plasma biomarkers to checkpoint inhibitors in patients with metastatic #melanoma.  We found several known and novel regulated proteins associated to progression-free survival.   💡 Complex solutions also require: ✔ Close collaborations, and in this case, the Jesper Velgaard Olsen group at the Novo Nordisk Foundation Center for Protein Research, University of Copenhagen and the biotech company Evosep Biosystems ✔Funding: this work is funded by the Novo Nordisk Foundation, European Research Council (ERC) and Innovation Fund Denmark   #olsengroup #plasmaproteomics #evosepbiosystems #immunotherapy

Have you read our case study, Measuring the Endogenous Expression of Peroxisomal Proteins using Highly Sensitive Dual-Luciferase® Reporter Technology and the GloMax® Discover featuring Dr Ruth Carmichael, University of Exeter on our website? The aim of Dr Carmichael’s research is to better understand how peroxisomal proteins are regulated in human cells, as very little is currently known about this process. She is investigating how peroxisome size and number is controlled within the cell, how they respond to the environment and how they communicate with other organelles. These findings could then be exploited for the development of therapeutics for diseases in which peroxisome regulation is dysfunctional. During the case study video, Dr Carmichael describes how the small size and sensitivity of NanoLuc luciferase, and the simplicity of the Nano-Glo DLR assay, has enabled her to develop a quick and easy method for studying peroxisomal protein expression that produces highly reproducible results, and can also be scaled up for high-throughput screening. She explains how the GloMax Discover plate reader, further increases the speed and simplicity of her experiments, as the software is very intuitive and Promega assay protocols are already preloaded onto the instrument. Read more at: https://bit.ly/3SS47PZ #LabChat #LabWork #PlateReader

"Moments when you realize nothing will ever be the same and time is divided into two parts - before this, and after this". Why use a Beacon Optofluidic System for Antibody Discovery? 🌟💡💡 - Achieve true single-cell dynamic resolution to observe complete cell behavior accurately. - Benefit from constant media perfusion support for uninterrupted studies. - Conduct sequential assays on a single cell to pinpoint IgG isotype, antigen specificity, conformational accuracy and species cross-reactivity against beads and cells. - Utilize end-to-end solutions for antibody-secreting cells sourced from various species like mouse, human, and rabbit. - Evaluate multiple functional characteristics concurrently, including epitope blocking, alongside other functional binding assessments. - All of these advanced capabilities are offered on the same single cell - replicated across 1000s of nanolitre pens! 🧬 Learn more at: https://lnkd.in/eCHBnZVW #AntibodyDiscovery #OptofluidicSystem #InnovativeResearch #Science #Biotechnology #Bruker #Enlightened #affinity #seethelight

1. Researchers from the University of Cincinnati developed a new method to accelerate drug discovery, aiming to shorten the timeline from years to months. 2. The study was published in Science Advances on August 30. 3. The method combines data from the LINCS database and targeted docking simulations to identify potential drugs. 4. This approach significantly reduces screening time from weeks to just an afternoon. 5. The new method is not only faster but also more efficient in identifying effective compounds. 6. It offers hope for treatments of diseases with no known cures, including cancer. 7. The accelerated process could enhance responses to public health crises, like the COVID-19 pandemic. 8. The study emphasizes the potential for more targeted treatment options in precision medicine.

It was an absolute pleasure to co-chair the Novel Technologies Workgroup at the invitation of Crohn's & Colitis Foundation for the new, 2024 version of Challenges in IBD. This was a year-long process and many colleagues, across disciplines have contributed. I am grateful to colleagues with expertise in clinical IBD, as well as engineering and science. We have identified 3 main gaps, that we think are addressable by novel technologies, over the next 5 years. First gap is in the diagnostic realm, where we believe that novel technologies can provide with earlier, more precise diagnostics. The second gap is in novel therapeutics - either targeted, or sustained release, or more precise. The third gap is in the collaboration among stakeholders - including clinicians, scientists, engineers and patients. We offer potential solutions, and hope this document will serve as a roadmap for both scientific endeavors, as well as funding decisions, over the next 5 years. Special thanks to Alan Moss, Andres Hurtado-Lorenzo, PhD, Russell Wyborski and Nicole MJ Schwerbrock! https://lnkd.in/d2JQXAEH

Meet Amelie Eriksson Karlström, Professor of Molecular Biotechnology at KTH! Amelie's research focuses on protein engineering, affinity technologies, and bioconjugation chemistry. Her team is developing innovative technologies for diagnostic and therapeutic applications, with a special emphasis on targeted radionuclide therapy for cancer. "I like to learn new things and I am motivated by unexpected findings. I also really like designing and building molecules." She highlights antibody therapies as a key breakthrough impacting her work, especially in the development of antibody-drug conjugates and radioimmunoconjugates. "New biotechnological methods will make it possible to develop therapies that are more efficient and have fewer side effects than today’s drugs. This will make treatments more accessible to a larger patient population." #LifeScience #Biotechnology #Research #GlobalHealth #KTH